File No. 12-167/2009-DC
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(Subsequent New Drugs Division)

Dated 11 DEC 2019

To,

M/s. Dispo Surgicals,
95, Surya Niketan, Vikas Marg,
Delhi 110092

Subject: Permission for conducting Phase-IV clinical trial "Multicenter Study to Evaluate the Safety and Efficacy of Lipidol ® Ultra Fluid druing conventional Transarterial chemoembolization (cTACE) in the treatment of inoperable Hepatocellular Carcinoma (HCC) in Indian Patients" - regarding.

CT NOC No. CT/SND/112/2019

Sir,

This Directorate has no objection to your conducting the subject mentioned clinical trial as per the provisions of Drugs & Cosmetics Rules under supervision of the following investigator and as per the **Protocol No: LUF-44-005, Phase IV, and Version 2, Dated 21-10-2019** submitted to this Directorate. Subject to the following Conditions:

1. Safety assessment should be the primary objective.
2. Contrast enhanced MRI Imaging should be done for follow-up after cTACE.
3. The study drug with other concomitant medication and test procedures should be provided free of cost to the trial participants as per GCP guidelines.

S. No	Investigator and Trial site	Ethics Committee Name and Registration Number
1	Dr. Pole Shivaji Marotrao, MGM Medical College & Hospital, N-6, Cidco, Aurangabad,	MGM Medical College & Hospital, N-6, Cidco, Aurangabad, Maharashtra 431003 **ECR/1083/MGM-CRHS/Inst/MH/2014/RR-2017**
2	Dr. Banode Pankaj, Jawaherlal Acharya Vinoba Bhave Rural Hospital, Datta Meghe Institute of Medical Science, Sawangi(Meghe), Wardha-442002, Maharashta-India	Institutional Ethics Committee, Sharad Pawar dental College, A Constituent College of Datta Meghe Institute of Medical Science(Deemed university) office of the Dean, Ground Floor, SPDC Building , Sawangi(Meghe), Wardha-442002, Maharashta-India. **EC/RENEW/INST/2019/4891**
3	Dr. Navin Mallikarjun Mulimani, KLE University, JN Medical College, Nehru Nagar, Belgavi-590010, Karnataka, India	Institutional Ethics Committee, KLE University, JN Medical College, Nehru Nagar, Belgavi-590010, Karnataka, India

		ECR/211/Inst/KA/2013/RR-19
4	Dr. Rathod Jawahar Rajusingh Government Medical College, Near Hanuman Nagar, Nagpur- 440 009 Nagpur Maharashtra India	Institutional Ethics Committee, GMC,Nagpur Government Medical College and Hospital, NagpurGovernment Medical College, Medical Square, Hanuman Nagar Nagpur Nagpur Nagpur Maharashtra **ECR/43/Inst/MH/2013/RR-19**
5	Dr. Doshi Soham Sunilkumar, Dr. Vasantrao Pawar Medical College,Hospital & Research Center Mumbai-Agra National Hwy, Vasantdadanagar, Adgaon, Nashik, Maharashtra 422207	Institutional Ethics Committee, Dr. Vasantrao Pawar Medical College,Hospital & Research Center Mumbai-Agra National Hwy, Vasantdadanagar, Adgaon, Nashik, Maharashtra **ECR/150/Inst/MH/2013/RR-19**
6	Dr. Suyash Kulkarni, Tata memorial Hospital, Dr. E, Dr. Ernest Borges Rd, Parel, Mumbai, Maharashtra 400012	Institutional Ethics Committee-II TATA Memorial HospitalIEC-II Office, Main Building, IIIrdFloor Ernest Borges Road, Parel, Mumbai Maharashtra –400012, India **ECR/414/Inst/MH/2013/RR-19**
7	Dr. Srinivas M R, Victoria Hospital, Bangalore Medical College & Research Institute (BMCRI) Victoria Hospital, Bangalore Medical College & Research Institute, Fort, K.R. Road. Bangalore Karnataka India 560002	Ethics Committee, Banglore Medical College and Reseach Institute, 1st Floor, K.R. Road, Bengaluru **ECR/302/Inst/KA.2013/RR-16**
8	Dr Raghunandan Prasad, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGI) Raebarelli Road, Lucknow- 226 014 Uttar Pradesh, India, 226014	Bio ethics cell, room no 205, First Floor, ADM Block, Sanjay Gandhi Postgraduate Institute of Medical Sciences (S G P G I) Raebarelli Road, Lucknow- 226 014 Uttar Pradesh, India **ECR/16/Inst/UP/2013/RR-16**

Kindly note that this permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940:

(i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;

(ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the center, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence center, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(iv) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;

(ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the
Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;

(xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;

(xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the

Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorized by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xv) The Laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

Yours faithfully,

(Dr. V. G. Somani)
Drugs Controller General (India)
(Name & Designation of Licensing Authority)